Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...

Pediatric cancer hospitalizations are approximately 2.5 times costlier than adult admissions, reflecting longer stays and ...

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...

As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...

Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

The STAND Act (HR 6835) expands spinal cord injury care via annual preventive evaluations and improved access to prosthetics and assistive mobility devices for eligible veterans. The Travel Assistance ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

Key Takeaways. Caregiver fear and availability meaningfully influence patient willingness to pursue CAR T and other immune effector therapies, contributing to persistently low uti ...